O'Shaughnessy Asset Management’s Denali Therapeutics DNLI Stock Holding History

O'Shaughnessy Asset Management’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-6,687	Closed	-$298K	–	1297
2021 Q4	$298K	Sell	6,687 -19	-0.3%	-$900	0.01%	875
2021 Q3	$339K	Sell	6,706 -349	-5%	-$19.7K	0.01%	800
2021 Q2	$553K	Sell	7,055 -838	-11%	-$51.8K	0.01%	619
2021 Q1	$450K	Hold	7,893	–	–	0.01%	646
2020 Q4	$661K	Buy	7,893 +7,868	+31,472%	+$476K	0.02%	444
2020 Q3	$1K	Hold	25	–	–	﹤0.01%	1718
2020 Q2	$1K	Buy	+25	New	+$588	﹤0.01%	1581

Other funds holding DNLI

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

O'Shaughnessy Asset Management's DNLI Position: Q1 2022 in Review

O'Shaughnessy Asset Management sold out of Denali Therapeutics (DNLI) in Q1 2022, closing a stake of 6,687 shares — an estimated $298K sold.

O'Shaughnessy Asset Management first reported a position in DNLI in Q2 2020 and held it in 7 quarters. The position peaked at $661K in Q4 2020. 190 funds tracked by Wall St. Rank hold DNLI as of Q1 2022.

O'Shaughnessy Asset Management reported no remaining Denali Therapeutics position as of Q1 2022 after selling out during the quarter.
O'Shaughnessy Asset Management sold 6,687 Denali Therapeutics shares in Q1 2022, an estimated $298K.
O'Shaughnessy Asset Management first reported a position in Denali Therapeutics in Q2 2020 and held it in 7 quarters.
O'Shaughnessy Asset Management's Denali Therapeutics position peaked at $661K in Q4 2020.
190 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2022.

Based on O'Shaughnessy Asset Management's 13F filing for Q1 2022, filed 13 May 2022.